Increased integration of artificial intelligence–based tools across the discovery and engineering of tumor-targeting engagers and multi-domain proteins to accelerate development while reducing developmental costs. Reduces reliance on trial-and-error experimentation, shortens development timelines, and increases likelihood that pipeline candidates demonstrate robust binding and functional activity suitable for translational advancement. GT Biopharma anticipates multiple new development candidates moving into pre-IND development in 2027, with potential targets and indications expanding beyond oncology. SAN FRANCISCO, CALIFORNIA, June 01, 2026 (GLOBE NEWSWIRE) — GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company’s proprietary natural killer (NK) cell engager TriKE® platform. “We have seen a marked acceleration in our discovery productivity following recent initiatives implementing AI-based technologies, which have been adapted to improve our drug engineering capabilities,” said Michael Breen, Executive Chairman and Chief Executive Officer.
This excerpt is quoted from the original release. Read the full announcement on GlobeNewsWire.
Brief Summary
GT Biopharma has announced significant advancements utilizing AI technologies to enhance their pipeline discovery. This integration is expected to transform drug development processes, enabling faster and more efficient candidate selection for pre-IND development. Key highlights include:
- Increased productivity in discovering tumor-targeting engagers.
- Decreased reliance on extensive trial-and-error procedures.
- Shortened timelines for drug development.
- Enhanced likelihood of candidates showing promising translational activity.
- Expansion of targets beyond oncology anticipated by 2027.
Why it matters: The implementation of AI-based initiatives positions GT Biopharma as a frontrunner in innovative therapeutic development, potentially leading to a diverse pipeline of candidates.
Read the Full Article
This is a summary of the press release. For the complete article and any additional details, please visit the original source.
Attribution: Original press release by GlobeNewsWire on . We provide an AI-generated summary and links for convenience. Always verify details with the original source. Not investment advice. For informational purposes only.